Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 14/20 | 0.65 |
| ▸ | CA1 | P00915 | 13/20 | 0.58 |
| ▸ | CA2 | P00918 | 13/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18517643 | 0.90 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL10035688 | 0.87 | FOLH1 (0.58) | CA9CA1CA2CA12USP2 | |
| SCHEMBL17522975 | 0.87 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL16521412 | 0.86 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14411388 | 0.85 | CA9 (0.65) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14089616 | 0.84 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13815114 | 0.83 | CA1 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL22030342 | 0.83 | CA1 (0.67) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19545067 | 0.83 | CA9 (0.67) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13219607 | 0.82 | CA1 (0.72) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119653-B2 | Belactosin derivatives as therapeutic agents/biological probes and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-7737134-B2 | Anticancer agents and use | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-02-12 | — | — | US | disclosed |
| US-20070149581-A1 | Potent immunosuppressive agents derivatives and use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149581-A1 | Potent immunosuppressive agents derivatives and use | EIF4A1, EIF4A3, EIF4EBP1 | CA9 4542/4885CA1 4181/4885CA2 4305/4885 |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | PSMB1, PSMB10, PBK | CA9 3815/4885CA1 4049/4885CA2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.